| Filed On | Filing |
|---|---|
| 08 Oct 2026 | SCHEDULE 13D/A |
| 28 Sep 2026 |
8-K: Other Events
On September 25, 2026, Gossamer Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price ... |
| 28 Sep 2026 | SCHEDULE 13D/A |
| 25 Sep 2026 |
Form 4: Milligan Sandra, Director
Granted 10,000 Stock Option (Right to Buy) |
| 25 Sep 2026 |
Form 4: Daniel Thomas O, Director
Granted 10,000 Stock Option (Right to Buy) |
| 25 Sep 2026 |
Form 4: Ciongoli Gregory Austin, Director
Granted 30,000 Stock Option (Right to Buy) |
| 25 Sep 2026 |
Form 4: Drynan Skye, Director
Granted 10,000 Stock Option (Right to Buy) |
| 25 Sep 2026 |
Form 4: Quisel John D, Director
Granted 10,000 Stock Option (Right to Buy) |
| 25 Sep 2026 |
Form 4: Cox Russell J., Director
Granted 10,000 Stock Option (Right to Buy) |
| 25 Sep 2026 |
Form 4: Nathan Steven D, Director
Granted 10,000 Stock Option (Right to Buy) |
| 23 Sep 2026 |
8-K: Other Events
On September 23, 2026, Gossamer Bio, Inc. (the “Company”) announced that it submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in September 2026 for seralutinib for the treatment of pulmonary arteri... |
| 22 Sep 2026 | Form 3: Ciongoli Gregory Austin, Director |
| 16 Sep 2026 | Proxy statement: special meeting on October 27, 2026 |
| 16 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
SAN DIEGO — (BUSINESS WIRE) — September 16, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hype... |
| 11 Sep 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
SAN DIEGO—(BUSINESS WIRE)— September 11, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment... |
| 09 Sep 2026 |
8-K: Other Events
SAN DIEGO—(BUSINESS WIRE)— September 9, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment ... |
| 04 Sep 2026 | D |
| 03 Sep 2026 | PRE 14A |
| 03 Sep 2026 | 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year |
| 26 Aug 2026 |
Form 4: Peterson Caryn, Chief Development Officer
Granted 5,800,051 Stock Option (Right to Buy) |
Loading...
